现代公司的新型结合流感和COVID-19疫苗显示出有前景,但面临FDA批准延误. Moderna’s new combined flu and COVID-19 vaccine shows promise but faces FDA approval delays.

Moderna 的新型流感和 COVID-19 联合疫苗显示出有希望的结果，为 50 岁及以上的人群产生比单独疫苗更强的免疫反应。 Moderna's new combination flu and COVID-19 vaccine shows promising results, generating a stronger immune response than individual vaccines for those 50 and older. 使用MRNA技术的疫苗报告了常见的副作用,如疼痛、疲劳和头痛。 The vaccine, which uses mRNA technology, reported common side effects like pain, fatigue, and headaches. 然而,林业发展局需要更多数据,以证明它在批准前预防疾病,可能将其提供推迟到2026年。 However, the FDA requires more data to prove it prevents illness before approval, likely delaying its availability until 2026.